GMAB
Income statement / Annual
Last year (2025), Genmab's total revenue was $3.72 B,
a decrease of 82.70% from the previous year.
In 2025, Genmab's net income was $963.76 M.
See Genmab,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$3.72 B |
$21.53 B |
$16.47 B |
$14.51 B |
$8.42 B |
$10.11 B |
$5.37 B |
$3.03 B |
$2.37 B |
$1.82 B |
| Cost of Revenue |
$309.24 M
|
$985.00 M
|
$226.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$3.41 B
|
$20.54 B
|
$16.25 B
|
$14.51 B
|
$8.42 B
|
$10.11 B
|
$5.37 B
|
$3.03 B
|
$2.37 B
|
$1.82 B
|
| Gross Profit Ratio |
0.92
|
0.95
|
0.99
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$1.56 B
|
$9.75 B
|
$7.63 B
|
$5.56 B
|
$4.18 B
|
$3.14 B
|
$2.39 B
|
$1.43 B
|
$874.28 M
|
$660.88 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$661.00 M
|
$342.00 M
|
$213.70 M
|
$146.99 M
|
$102.41 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$602.47 M
|
$3.79 B
|
$3.30 B
|
$2.68 B
|
$1.28 B
|
$661.00 M
|
$342.00 M
|
$213.70 M
|
$146.99 M
|
$102.41 M
|
| Other Expenses |
$0.00
|
$300.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$2.16 B
|
$13.84 B
|
$10.93 B
|
$8.24 B
|
$5.46 B
|
$3.80 B
|
$2.73 B
|
$1.64 B
|
$1.02 B
|
$763.29 M
|
| Cost And Expenses |
$2.47 B
|
$14.82 B
|
$11.15 B
|
$8.24 B
|
$5.46 B
|
$3.80 B
|
$2.73 B
|
$1.64 B
|
$1.02 B
|
$763.29 M
|
| Interest Income |
$138.11 M
|
$995.00 M
|
$939.00 M
|
$324.00 M
|
$197.00 M
|
$184.00 M
|
$120.00 M
|
$62.92 M
|
$41.00 M
|
$32.58 M
|
| Interest Expense |
$61.05 M
|
$120.00 M
|
$27.00 M
|
$21.00 M
|
$13.00 M
|
$10.00 M
|
$7.00 M
|
$417.00 K
|
$2.00 M
|
$213.00 K
|
| Depreciation & Amortization |
$71.06 M
|
$413.00 M
|
$240.00 M
|
$362.00 M
|
$250.00 M
|
$246.00 M
|
$139.00 M
|
$87.70 M
|
$70.00 M
|
$40.96 M
|
| EBITDA |
$1.32 B |
$9.70 B |
$5.95 B |
$7.35 B |
$4.18 B |
$6.16 B |
$3.01 B |
$1.70 B |
$1.49 B |
$1.17 B |
| EBITDA Ratio |
0.36
|
0.45
|
0.36
|
0.51
|
0.5
|
0.61
|
0.56
|
0.56
|
0.63
|
0.64
|
| Operating Income Ratio |
0.34
|
0.31
|
0.32
|
0.43
|
0.35
|
0.62
|
0.49
|
0.46
|
0.57
|
0.58
|
| Total Other Income/Expenses Net |
-$46.04 M
|
$2.46 B
|
$316.00 M
|
$678.00 M
|
$965.00 M
|
-$409.00 M
|
$221.00 M
|
$231.69 M
|
-$280.45 M
|
$77.38 M
|
| Income Before Tax |
$1.20 B
|
$9.16 B
|
$5.64 B
|
$6.95 B
|
$3.92 B
|
$5.90 B
|
$2.86 B
|
$1.61 B
|
$1.06 B
|
$1.13 B
|
| Income Before Tax Ratio |
0.32
|
0.43
|
0.34
|
0.48
|
0.47
|
0.58
|
0.53
|
0.53
|
0.45
|
0.62
|
| Income Tax Expense |
$241.19 M
|
$1.32 B
|
$1.29 B
|
$1.49 B
|
$961.00 M
|
$1.15 B
|
$693.00 M
|
$139.83 M
|
-$39.83 M
|
-$56.86 M
|
| Net Income |
$963.76 M
|
$7.84 B
|
$4.35 B
|
$5.45 B
|
$2.96 B
|
$4.76 B
|
$2.17 B
|
$1.47 B
|
$1.10 B
|
$1.19 B
|
| Net Income Ratio |
0.26
|
0.36
|
0.26
|
0.38
|
0.35
|
0.47
|
0.4
|
0.49
|
0.47
|
0.65
|
| EPS |
1.55 |
12.14 |
6.6 |
8.34 |
4.52 |
7.3 |
3.44 |
2.4 |
1.81 |
1.98 |
| EPS Diluted |
1.54 |
12.14 |
6.6 |
8.26 |
4.48 |
7.22 |
3.4 |
2.37 |
1.78 |
1.92 |
| Weighted Average Shares Out |
$621.51 M
|
$646.34 M
|
$659.19 M
|
$653.87 M
|
$653.96 M
|
$651.79 M
|
$629.63 M
|
$612.68 M
|
$608.34 M
|
$598.76 M
|
| Weighted Average Shares Out Diluted |
$626.92 M
|
$646.33 M
|
$659.15 M
|
$660.10 M
|
$660.46 M
|
$658.86 M
|
$636.37 M
|
$620.45 M
|
$620.94 M
|
$617.66 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
